talen stock price today

Is Talen Energy (TLN) stock getting good media coverage?

Talen Energy trades on the New York Stock Exchange (NYSE) under the ticker symbol "TLN.". Media coverage about TLN stock has trended somewhat positive recently, InfoTrie reports. InfoTrie identifies positive and negative media coverage by reviewing more than six thousand news and blog sources in real-time.

Who buys tals stock?

TALS stock was bought by a variety of institutional investors in the last quarter, including Northern Trust Corp, Altium Wealth Management LLC, ProShare Advisors LLC, Bank of America Corp DE, and New York State Common Retirement Fund. View insider buying and selling activity for Talaris Therapeutics or or view top insider-buying stocks.

What is (TLN)'s stock price?

(TLN) trades on the New York Stock Exchange (NYSE) under the ticker symbol "TLN." What is (TLN)'s stock price today? One share of TLN stock can currently be purchased for approximately $14.00.

Is talaris Therapeutics a good stock to buy?

62.57% of the stock of Talaris Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Earnings for Talaris Therapeutics are expected to grow in the coming year, from ($1.54) to ($1.38) per share. Is Talaris Therapeutics a buy right now?

What other stocks do shareholders of (TLN) own?

Based on aggregate information from My MarketBeat watchlists, some companies that other (TLN) investors own include PPL (PPL) , HCI Group (HCI) ,...

What is (TLN)'s stock symbol?

(TLN) trades on the New York Stock Exchange (NYSE) under the ticker symbol "TLN."

What is (TLN)'s stock price today?

One share of TLN stock can currently be purchased for approximately $14.00.

What is (TLN)'s official website?

The official website for (TLN) is www.talenenergy.com .

How can I contact (TLN)?

(TLN)'s mailing address is 835 Hamilton St, ALLENTOWN, PA 18101-2426, United States . The utilities provider can be reached via phone at +1-610-7...

Where is Talen Energy located?

What other stocks do shareholders of (TLN) own?

The Company generates and sells electricity, capacity and related products from power plants that use fuel sources, such as nuclear, natural gas and coal. The Company's Susquehanna nuclear power plant has approximately two boiling water reactors with a combined capacity of over 2,600 megawatts. Its fossil fuel plants are located in Athens, Barney Davis, Bayonne, Brandon Shores, Brunner Island, Camden, Colstrip and Dartmouth, among others. It has an art energy trading center located in Allentown, Pennsylvania (PA), where it manages asset load obligations, fuel supply, capacity and related products, and all supporting physical or financial transactions for its electric generation portfolio.

What percentage of Tln is held by institutions?

Based on aggregate information from My MarketBeat watchlists, some companies that other (TLN) investors own include PPL (PPL), HCI Group (HCI), Supervalu (SVU), Key Tronic (KTCC), Diana Shipping (DSX), Ring Energy (REI), Ultra Clean (UCTT), U.S. Bancorp (USB), Devon Energy (DVN) and (FMSA) (FMSA).

What is the official website for Tln?

98.98% of the stock of (TLN) is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

When will Talos start producing?

The official website for (TLN) is www.talenenergy.com.

How many acres are there in the Talos lease?

Talos Energy Inc. ("Talos" or the "Company") (NYSE: TALO) today announced preliminary production estimates for the second quarter of 2021, successful first production from the Company's Tornado Attic well and successful drilling of the Company's Crown and Anchor well.

Is Talos Energy a public company?

(NYSE: TALO) ("Talos" or the "Company") today announced that it was named as the apparent high bidder in the Outer Continental Shelf Federal Lease Sale 257 on ten deepwater blocks comprising 57,600 gross acres, or 36,720 net acres, for a net total consideration of approximately $4.8 million. Nine of the blocks are in close proximity to the Company's operated Green Canyon and Mississippi Canyon facilities, while the remaining block offsets the Company's recent Puma West discover

When will Talaris be available in 2021?

Talos Energy Inc. (NYSE: TALO) ("Talos" or the "Company") announced today an underwritten public offering of an aggregate of 6,000,000 shares of its common stock (the "Offering") by certain affiliates of Apollo Global Management and Riverstone Holdings LLC (the "Selling Stockholders"). Talos is not selling any shares of common stock in the Offering and will not receive any proceeds from any sale of shares by the Selling Stockholders.

What is Talaris Therapeutics?

(Nasdaq: TALS), a late-clinical stage cell therapy company developing therapies with the potential to transform the standard of care in solid organ transplantation, certain severe autoimmune diseases, and certain severe non-malignant blood, immune and metabolic disorders, today reported financial results for the three-month period ended March 31, 2021, and provided an update on its business. “Following our s

Is Talaris Therapeutics a late stage company?

, May 11, 2021 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-clinical stage cell therapy company developing therapies with the potential to transform the standard of care in solid organ transplantation, certain severe autoimmune diseases, and certain severe non-malignant blood, immune and metabolic disorders, today announced the closing of its initial public offering of 8,825,000 shares of its common stock at a price to the public of $17.00 per share. The gross proceeds of the offering were approximately $150.0 million, before deducting underwriting discounts and commissions and other offering expenses. The shares began trading on the Nasdaq Global Market on May 7, 2021 under the symbol “TALS.” All shares in the offering were offered by Talaris Therapeutics. In addition, the underwriters have a 30-day option to purchase up to an additional 1,323,750 shares of common stock at the initial public offering price less underwriting discounts and commissions. Morgan Stanley, SVB Leerink, Evercore ISI and Guggenheim Securities are acting as joint book-running managers for the offering. A registration statement relating to these securities has been filed and was declared effective by the Securities and Exchange Commission on May 6, 2021. This offering was made only by means of a written prospectus. Copies of the final prospectus relating to the initial public offering can be obtained, when available, from: Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, NY 10014; SVB Leerink LLC, Attention: Syndicate Department, One Federal Street, 37th Floor, Boston, MA 02110, by telephone at (800) 808-7525, ext. 6105, or by email at [email protected]; Evercore Group L.L.C., Attention: Equity Capital Markets, 55 East 52nd Street, 35th Floor, New York, NY 10055, or by telephone at (888) 474-0200, or by email at [email protected]; and Guggenheim Securities, LLC, Attention: Equity Syndicate Department, 330 Madison Avenue, New York, NY 10017, by telephone at (212) 518-5548, or by email at [email protected]. This press release does not constitute an offer to sell or a solicitation of an offer to buy these securities, nor will there be any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful before registration or qualification under the securities laws of that state or jurisdiction. About Talaris Therapeutics Talaris Therapeutics, Inc. is a late-clinical stage cell therapy company developing an innovative method of allogeneic hematopoietic stem cell transplantation with the potential to transform the standard of care in solid organ transplantation, certain severe autoimmune diseases, and certain severe non-malignant blood, immune and metabolic disorders. Talaris maintains corporate offices in Boston, Mass., and its cell processing facility in Louisville, Ky. Media Contact: Lisa RaffenspergerTen Bridge [email protected] (617) 903-8783

What is Talaris Therapeutics' stock symbol?

BOSTON and LOUISVILLE, Ky., Nov. 08, 2021 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-clinical stage cell therapy company developing therapies with the potential to transform the standard of care in solid organ transplantation, certain severe autoimmune diseases, and certain severe non-malignant blood, immune and metabolic disorders, today announced that members of its senior management team will participate at the following investor conferences: Virtual Guggenheim 3rd

When will Talaris Therapeutics release its earnings?

Talaris Therapeutics trades on the NASDAQ under the ticker symbol "TALS."

What is marketbeat ratings?

Talaris Therapeutics is scheduled to release its next quarterly earnings announcement on Monday, September 13th 2021. View our earnings forecast for Talaris Therapeutics.

What is Talaris Therapeutics?

MarketBeat's community ratings are surveys of what our community members think about Talaris Therapeutics and other stocks. Vote “Outperform” if you believe TALS will outperform the S&P 500 over the long term. Vote “Underperform” if you believe TALS will underperform the S&P 500 over the long term. You may vote once every thirty days.

Does Talaris Therapeutics pay dividends?

Talaris Therapeutics, Inc. operates as a late-clinical stage cell therapy company in the United States. The company engages in developing a method of allogeneic hematopoietic stem cell transplantation to transform the standard of care in solid organ transplantation and severe autoimmune diseases, as well as severe non-malignant blood, immune, and metabolic disorders. Its lead product candidate is FCR001, a novel allogeneic cell therapy that is in Phase II trial for living donor kidney transplant patients. The company is also developing FCR002 in deceased donor kidney transplants; FCR001 in patients with a severe form of scleroderma; and FCR001 for one or more severe non-malignant blood, immune, or metabolic disorders. Talaris Therapeutics, Inc. was founded in 1988 and is headquartered in Louisville, Kentucky.